Interpretation of Pharmacovigilance Disproportionality Analyses
- PMID: 37248829
- DOI: 10.1002/cpt.2951
Interpretation of Pharmacovigilance Disproportionality Analyses
Comment in
-
Reply to "Interpretation of Pharmacovigilance Disproportionality Analyses".Clin Pharmacol Ther. 2023 Oct;114(4):747. doi: 10.1002/cpt.2950. Epub 2023 Jun 1. Clin Pharmacol Ther. 2023. PMID: 37259792 No abstract available.
Comment on
-
COVID-19 Vaccination and the Incidence of De Novo or Recurrent Rheumatoid Arthritis: A French and International (VigiBase) Signal Detection Study.Clin Pharmacol Ther. 2023 May;113(5):1107-1116. doi: 10.1002/cpt.2866. Epub 2023 Feb 27. Clin Pharmacol Ther. 2023. PMID: 36752604
References
-
- Prontskus, V. et al. COVID-19 vaccination and the incidence of De novo or recurrent rheumatoid arthritis: a French and international (VigiBase) signal detection study. Clin. Pharmacol. Ther. 113, 1107-1116 (2023).
-
- Faillie, J.-L. Case-non-case studies: principle, methods, bias and interpretation. Therapie 74, 225-232 (2019).
-
- Durand, J. et al. Safety monitoring of COVID-19 vaccines: perspective from the European medicines agency. Clin. Pharmacol. Ther. 113, 1223-1234 (2023).
-
- Mouffak, A. et al. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. J. Clin. Epidemiol. 138, 73-79 (2021).
-
- Boutron, I. & Ravaud, P. Misrepresentation and distortion of research in biomedical literature. Proc. Natl. Acad. Sci. 115, 2613-2619 (2018).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
